Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 443 results for blood monitoring

  1. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

  2. Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (TA1099)

    Evidence-based recommendations on durvalumab (Imfinzi) for treating limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults.

  3. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

  4. Prostatitis (acute): antimicrobial prescribing (NG110)

    This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

  5. Patient group directions (MPG2)

    This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

  6. Hepatitis B and C testing: people at risk of infection (PH43)

    This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

  7. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.

  8. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

  9. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.

  10. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

  11. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

  12. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

  13. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

  14. Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

    Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults.